Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.

Saved in:
Bibliographic Details
Title: Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.
Authors: Griffen EJ; MedChemica Consultancy Ltd, Motorworks, Chestergate, Macclesfield, SK11 6GU, UK., Fearon D; Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.; Research complex at Harwell. Harwell Science and Innovation Campus, Didcot, UK., McGovern BL; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Koekemoer L; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Balcomb BH; Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.; Research complex at Harwell. Harwell Science and Innovation Campus, Didcot, UK., Szommer T; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Fate G; Thames Pharma Partners LLC, Mystic, Connecticut, USA., Robinson RP; Thames Pharma Partners LLC, Mystic, Connecticut, USA., Lefker BA; Thames Pharma Partners LLC, Mystic, Connecticut, USA., Duberstein S; G-INCPM, Weizmann Institute of Science, Rechovot, Israel., Lahav N; G-INCPM, Weizmann Institute of Science, Rechovot, Israel., Braillard S; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Vangeel L; Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium., Laporte M; Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium., Charvillon FB; Drugs for Neglected Diseases initiative, Geneva, Switzerland., MacLeod AK; Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK., Wells A; Charnwood Technical Consulting, UK., Garner P; ApconiX, Mereside, Alderley Park, Cheshire, UK., Knight R; ApconiX, Mereside, Alderley Park, Cheshire, UK., Rees P; Compass Business Partners Ltd, Gerrards Cross, UK., Simon A; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Jochmans D; Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium., Neyts J; Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium., Read KD; Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK., Barr H; G-INCPM, Weizmann Institute of Science, Rechovot, Israel., Robinson M; PostEra Inc., Cambridge, MA 02142, USA., Lee A; PostEra Inc., Cambridge, MA 02142, USA., London N; Department of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel., Chodera J; Program in Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., von Delft F; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.; Department of Biochemistry, University of Johannesburg, Auckland Park, Johannesburg 2006, South Africa.; Research complex at Harwell. Harwell Science and Innovation Campus, Didcot, UK., White KM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Perry B; Drugs for Neglected Diseases initiative, Geneva, Switzerland., Sjö P; Drugs for Neglected Diseases initiative, Geneva, Switzerland., von Delft A; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Corporate Authors: COVID Moonshot Consortium
Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Jun 17. Date of Electronic Publication: 2025 Jun 17.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.1101/2025.06.16.660018